[American Journal of Obstetrics & Gynecology] A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement
[Journal of Contraception] Levonorgestrel release rates over five years with the Liletta™ 52 mg intrauterine system
Medicines360 and Population Services International Announce New Partnership to Expand Access to Hormonal IUDs to Women in Africa
Medicines360, a global nonprofit pharmaceutical company, and Population Services International (PSI), a leading global health organization working in reproductive health, announced today an agreement to expand access to Medicines360’s hormonal intrauterine device (IUD) (levonorgestrel-releasing intrauterine system) 52 mg.
Allergan and Medicines360 Announce Donation of Intrauterine Devices (IUD) to the Centers for Disease Control (CDC) Foundation to Help Address Microcephaly Impact from Zika Virus in Puerto Rico
Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that they will donate 10,000 units of their hormonal IUD, LILETTA®.
Could The Most Effective Birth Control Soon Become The Cheapest?
The most effective reversible forms of birth control are mostly priced out of reach for millions of women who need it most—until now. An unusual partnership between a nonprofit pharmaceutical company and a traditional pharmaceutical distributor aims to increase access to IUDs (intrauterine devices) for U.S. servicewomen and in public clinics.
[Journal of Obstetrics & Gynecology] Return of spontaneous menses and fertility after removal of the Liletta™ levonorgestrel intrauterine system
Medicines360 Announces New Partnership With Marie Stopes International To Expand Access To Its Hormonal IUD To Women In Kenya, East Africa
Medicines360, a global nonprofit pharmaceutical company, today announced an agreement with Marie Stopes International (MSI), a global nonprofit family planning organization, to expand access to Medicines360’s hormonal intrauterine device, LNG IUS (levonorgestrel-releasing intrauterine system, 52mg), bringing further contraceptive options to the women of Kenya.
[Contraception] Assessment of expulsions in nulliparous and multiparous women during the first year of use of Liletta™, a new 52 mg levonorgestrel-releasing intrauterine system
[Contraception] Amenorrhea rates during the first year of use of Liletta™, a new 52 mg levonorgestrel-releasing intrauterine system
Medicines360 Names Jessica Grossman as CEO
Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the company has appointed Jessica Grossman, M.D., as its Chief Executive Officer, effective immediately. Dr. Grossman has been chair of the Board of Directors of Alliance Partners360, Medicines360’s for-profit subsidiary, since 2014 and a director of Medicines360 since 2011.
